LONDON--(BUSINESS WIRE)--LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow Extracorporeal Membrane Oxygenation (ECMO) cannula earned ...
Use of left atrial venoarterial cannulation during extracorporeal membrane oxygenation—a technique known as LAVA ECMO—appears to be a safe and feasible means of support for patients with cardiogenic ...
Although use of ECMO carries certain complications, its potential benefits can be pivotal in saving lives in critical care. ECMO carries certain complications associated with its use. Extra Corporeal ...
The pneumonia presented with the novel coronavirus disease 2019 can lead to severe respiratory failure with profound hypoxemia that requires endotracheal intubation and mechanical ventilation.
The current trend of using two cannulas to place most newborns in respiratory failure on life-sustaining ECMO, one in the right internal jugular vein and a second in the right common carotid artery, ...
Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days’ use LONDON--(BUSINESS WIRE)-- LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, ...
Bi-Flow is first bidirectional femoral arterial cannula validated for 29 days' use LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced its Bi-Flow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback